Co-stimulatory Molecules Improve the Immune Response to a Weak Neoantigen
Therapeutic cancer vaccines are an emerging cancer immunotherapy that work by educating the host’s immune system to attack cancer cells within the body. mRNA lipid nanoparticle (LNP) cancer vaccines are one popular method to deliver tumor specific antigens, termed neoantigens. However, they often do not initiate strong enough CD8+ and CD4+ Type 1 helper (Th1) T cell activation to combat the solid tumors. Thus, it is critical for neoantigen-based cancer vaccines to be delivered with adjuvants to effectively activate neoantigen specific T-cells. Co-stimulatory molecule could act as an alternative adjuvant, because co-stimulatory molecule signaling is the second most crucial signal for T cell activation. Here we aim to co-deliver a pancreatic cancer neoantigen with co-stimulatory molecules via mRNA LNPs. Six co-stimulatory molecules known to increase Th1 T-Cell responses were tested as possible adjuvants for a low-immunogenic neoantigen. Results show three of the six co-stimulatory molecules were able to increase the interferon gamma (IFN-g) immune response of the neoantigen: OX40L, GITRL, and CD80. We then tested whether combinations of these three could further increase the IFN-g immune response. Results show that the combination of OX40L and CD80 significantly increased the IFN-g immune response of the neoantigen 3.3-fold. The study showed individual co-stimulatory molecules and combinations of molecules can increase the IFN-g immune response of a weakly stimulating neoantigen. Co-stimulatory molecules could be ideal adjuvants for neoantigen-based mRNA LNP cancer vaccines.